Peer Review | Agreement Across 10 Artificial Intelligence Models in Assessing Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Breast Cancer Whole-Slide Images | January 5, 2026 Share
Peer Review | Enabling access to genetically modified cell therapies through flexible approaches to manufacturing and cost recovery | December 2, 2025 Share
Peer Review | Hurry Up and Wait: Timelines and Takeaways from the Biomarker Qualification Program | October 28, 2025 Share
Peer Review | Molecular response cutoffs and ctDNA collection timepoints influence on interpretation of associations between early changes in ctDNA and overall survival in patients treated with anti-PD(L)1 and/or chemotherapy | September 24, 2025 Share
Peer Review | Impact of the COVID-19 Pandemic Mitigation Strategies on Cancer Treatment Trials: A Meta-Analysis of Industry and National Cancer Institute Studies | June 16, 2025 Share
Peer Review | Intentional heterogeneity in autologous cell-based gene therapies: strategic considerations for first-in-human trials | June 9, 2025 Share
Peer Review | Companion Diagnostic FDA Review Flexibilities: An Assessment of CDx for NSCLC to Support Aligned Approaches for Validation | May 20, 2025 Share
Peer Review | ctDNA Clearance as an Early Indicator of Improved Clinical Outcomes in Advanced NSCLC Treated with TKI: Findings from an Aggregate Analysis of Eight Clinical Trials | April 23, 2025 Share
Peer Review | An Analysis of 20 Independently Performed Assays to Measure Homologous Recombination Deficiency (HRD) in Ovarian Cancer: Findings from the Friends’ HRD Harmonization Project | November 4, 2024 Share
Peer Review | Sponsor Perspectives on the Impact of the COVID-19 Pandemic on Interventional Cancer Clinical Trial Protocols and Data Quality | September 9, 2024 Share
